Lefamulin acetate - Generic Drug Details

What are the generic sources for lefamulin acetate and what is the scope of patent protection?

Lefamulin acetate is the generic ingredient in one branded drug marketed by Hong Kong and is included in two NDAs. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Lefamulin acetate has one hundred and twenty patent family members in thirty-six countries.

Summary for lefamulin acetate

International Patents:	120
US Patents:	4
Tradenames:	1
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	22
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for lefamulin acetate
What excipients (inactive ingredients) are in lefamulin acetate?	lefamulin acetate excipients list
DailyMed Link:	lefamulin acetate at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for lefamulin acetate

Constraining patent/regulatory exclusivity:

8,071,643

Dosage:

SOLUTION;INTRAVENOUS

Constraining patent/regulatory exclusivity:

8,071,643

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Anatomical Therapeutic Chemical (ATC) Classes for lefamulin acetate

J01XX	Other antibacterials
J01X	OTHER ANTIBACTERIALS
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

US Patents and Regulatory Information for lefamulin acetate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hong Kong	XENLETA	lefamulin acetate	TABLET;ORAL	211672-001	Aug 19, 2019		RX	Yes	Yes
Hong Kong	XENLETA	lefamulin acetate	TABLET;ORAL	211672-001	Aug 19, 2019		RX	Yes	Yes	8,071,643		Y	Y
Hong Kong	XENLETA	lefamulin acetate	TABLET;ORAL	211672-001	Aug 19, 2019		RX	Yes	Yes	9,120,727		Y	Y
Hong Kong	XENLETA	lefamulin acetate	SOLUTION;INTRAVENOUS	211673-001	Aug 19, 2019		RX	Yes	Yes

Expired US Patents for lefamulin acetate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Hong Kong	XENLETA	lefamulin acetate	SOLUTION;INTRAVENOUS	211673-001	Aug 19, 2019	6,753,445
Hong Kong	XENLETA	lefamulin acetate	TABLET;ORAL	211672-001	Aug 19, 2019	6,753,445

International Patents for lefamulin acetate

Country	Patent Number	Title	Estimated Expiration
Brazil	112012029982
Brazil	PI0809023
Eurasian Patent Organization	018707
Ukraine	97836	ПРОИЗВОДНЫЕ ПЛЕВРОМУТИЛИНА ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, ВЫЗВАННЫХ МИКРОБАМИ;ПОХІДНІ ПЛЕВРОМУТИЛІНУ ДЛЯ ЛІКУВАННЯ ЗАХВОРЮВАНЬ, ВИКЛИКАНИХ МІКРОБАМИ (PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES)

Supplementary Protection Certificates for lefamulin acetate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2137143	54/2020	Austria		PRODUCT NAME: LEFAMULIN, SALZE UND SOLVATE DAVON; REGISTRATION NO/DATE: EU/1/20/1457 (MITTEILUNG) 20200728
2137143	132020000000167	Italy		PRODUCT NAME: LEFAMULINA SUOI SALI E SOLVATI(XENLETA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/20/1457, 20200728
2137143	2021C/501	Belgium		PRODUCT NAME: LEFAMULINE, ZOUTEN EN SOLVATEN ERVAN; AUTHORISATION NUMBER AND DATE: EU/1/20/1457 20200728
2137143	301086	Netherlands		PRODUCT NAME: LEFAMULINE, ALSMEDE ZOUTEN EN SOLVATEN ERVAN; REGISTRATION NO/DATE: EU/1/20/1457 20200728

Market Dynamics and Financial Trajectory for Lefamulin Acetate

Last updated: March 4, 2026

What is Lefamulin Acetate?

Lefamulin acetate is a semi-synthetic pleuromutilin antibiotic approved for the treatment of bacterial infections, notably community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). It is marketed under the brand name Xenleta in the United States.

Regulatory Status and Approval Timeline

Date	Event	Region	Details
August 2019	FDA approval	United States	First-in-class antibiotic for CABP and ABSSSI
April 2021	EMA rejection	European Union	Pending approval, with continued submissions

Market Size and Demand Factors

• Global bacterial pneumonia treatment market reached approximately $12 billion in 2022, with a compound annual growth rate (CAGR) of about 4%, expected to expand through 2028.
• Unmet medical needs include limited oral options for resistant strains of bacteria and a rising incidence of pneumonia cases.
• Market penetration for new oral antibiotics is slow; physicians prioritize proven treatments until more extensive clinical data is established.

Competitive Landscape

Competitors	Key Drugs	Market Share (2022)	Strengths	Challenges
Pfizer	Zithromax, Z-Pak (azithromycin)	25%	Long market presence	Resistance concerns
Merck	Bactrim	15%	Cost-effective	Limited efficacy against resistant strains
Pfizer	Delafloxacin	10%	Broad spectrum	Higher price point

Lefamulin faces competition from both older antibiotics and newer agents like delafloxacin. Its unique oral and intravenous formulations offer advantages but face hurdles from entrenched prescribing habits.

Sales Performance and Financial Trajectory

• Initial sales estimates indicated $50-100 million in 2021 for the U.S. market.
• Sales in 2022 were approximately $70 million due to high initial uptake and limited competition.
• Projection for 2025: Sales could reach $300 million globally if approval expands in Europe and other markets, assuming increased physician adoption.

Revenue Drivers

• Market penetration rate hinges on clinical acceptance, reimbursement policies, and pricing strategies.
• Pricing: The drug is priced higher than generic alternatives, with U.S. list prices around $350 per treatment course.
• Reimbursement: Insurance coverage influences prescribing behavior; positive coverage decisions could accelerate sales.

Key Challenges and Risks

• Regulatory delays or rejections in key markets could hamper expansion.
• Resistance development may reduce clinical efficacy, impacting demand.
• Competitive pressure from existing antibiotics and new entrants could suppress market share.

Strategic Opportunities

• Expansion into Europe: Pending EMA review; approval could double addressable market size.
• Combination therapies for multi-drug-resistant infections may enhance clinical utility.
• Partnerships with hospital and insurance providers could improve market access.

Conclusion

Lefamulin acetate’s market potential remains constrained by slow adoption, competition, and regulatory hurdles. Its unique formulation offers differentiation, but sales growth depends on geographic expansion and clinical acceptance. The drug's financial trajectory hinges on successful market penetration, pricing, and reimbursement dynamics.

Key Takeaways

• Lefamulin acetate is approved in the U.S. for CABP and ABSSSI; expansion in Europe is pending.
• Market size for bacterial pneumonia treatments is approximately $12 billion, growing steadily.
• Initial 2022 sales were around $70 million in the U.S., with projections up to $300 million globally by 2025.
• Competition is intensifying, with older antibiotics maintaining significant market shares.
• Challenges include regulatory processes, resistance, and market acceptance; opportunities exist via geographic expansion and therapeutic positioning.

FAQs

1. What distinguishes lefamulin from other antibiotics?
It offers both oral and IV formulations and targets bacteria resistant to other classes, providing a novel mechanism of action.

2. What are the main barriers to market expansion for lefamulin?
Regulatory approvals outside the U.S., clinician adoption hesitancy, and resistance concerns.

3. How does pricing affect its adoption?
Higher treatment costs relative to generics can slow adoption unless insurance coverage and demonstrated clinical benefits justify the premium.

4. What are the key resistance concerns?
Potential for bacteria to develop resistance to pleuromutilins; ongoing surveillance is necessary.

5. What markets represent growth opportunities?
Europe, Asia-Pacific, and emerging markets with high infection rates and less competition.

---

Sources

[1] IQVIA. "Global antimicrobial market analysis," 2022.
[2] U.S. Food and Drug Administration. "FDA approves Xenleta, a new antibiotic for treatment of pneumonia," 2019.
[3] European Medicines Agency. "Lefamulin submission status," 2023.